Decipher the Biology of Lethal Prostate Cancer—Using Urine Metabolomics Profiling to Search for Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer Patients

2017-08-03 13:23:21 | BioPortfolio


Prostate cancer (PC) afflicts millions of men worldwide. In Taiwan, around 5,000 men are diagnosed as PC while 1,200 men die of the disease each year. Although there is a significant advance in the definitive treatments of PC, the failure rate is still up to 40%. Androgen deprivation therapy (ADT) and chemotherapy (Chemo) are palliative and rarely curative. Immunotherapy brings on promise but is highly unpredictable. Thus, markers that predict treatment outcomes may help decision making and prompt early adjuvant or salvage therapy. Also, markers that mediate resistance to treatments may become druggable targets.

This is a prospective and observational clinical study investigating urine metabolites via metabolomics analysis in subjects who will undergo therapy for PC. The treatment modalities include radical prostatectomy (OP), prostate radiotherapy (RT), systemic Chemo, and ADT. The expected subject number to be enrolled is 360 men from NTUH. There will be 2 cohorts: training cohort (Cohort A, N=180), and validation cohort (Cohort B, N=180). Each cohort consists of patients treated with OP (N=50), RT (N=70), Chemo (N=30) and ADT (N=30). Cohort A will be recruited in the first 12 months of the study period to generate the first batch of urine metabolite profiles. Cohort B will be recruited in the second half of the study period to validate the first batch of newly developed urine metabolite profile.

Pre-treatment and post-treatment clinic-pathological parameters will be recorded. Group specific urine metabolite profiles will be constructed by comparing the outstanding metabolites between groups. These metabolite profiles are constructed so as to efficiently separate outcome groups, especially to predict subjects with good prognosis and response to the treatment. The newly constructed metabolite profiles will be validated against another cohort of subjects who will receive therapy for PC to determine the predictive efficiency of the constructed profiles. In addition, paraffin blocks of the prostate cancer will be used to identify progression markers for invasion and metastasis, as well as progression markers for castration-resistant PC.

Through a better understanding of the biology of PC, we hope to develop new markers/targets for more effective predicting outcomes of PC. In the meantime, we can also substantially develop a better decision-making tree of PC.

Study Design


Using Urine Metabolomics Profiling to Search for Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer Patients


No intervention required


Not yet recruiting


National Taiwan University Hospital

Results (where available)

View Results


Published on BioPortfolio: 2017-08-03T13:23:21-0400

Clinical Trials [1022 Associated Clinical Trials listed on BioPortfolio]

Exploratory Study of Relationships Between Malodor and Urine Metabolomics

The purpose of this study is to identify metabolic signatures associated with malodor conditions. The investigators will perform state-of-the art metabolomics tests and bioinformatic data ...

Metabolomics for Biomarker Discovery in Children With EoE

The investigators are seeking to enroll 8 children ages 2-18 already undergoing upper endoscopy. For the purposes of research, a peripheral blood and clean catch urine specimen will be obt...

Using Preprocedural Urine NMR(Nuclear Magnetic Resonance) -Based Metabolomics Analysis

The use of coronary intervention has increased over the last decade. Contrast induced nephropathy (CIN) that develops as a result of procedures using intravenous or intra arterial contrast...

Change of Urinary Metabolic Profile Secondary to a Congenital Urine Flow Impairment (UFI) by Nuclear Magnetic Resonance (NMR) and Metabolomics Analysis

For the new-born, diagnosis and prognosis of congenital urine flow impairment (UFI) are difficult to confirm only with morphological examination (ultrasonography, intravenous pyelography) ...

Validation of a Test for Fetal Malformations

The investigators have developed a diagnostic test for the evaluation of the presence of fetal malformations through metabolomic analysis of maternal peripheral blood serum by chromatograp...

PubMed Articles [13721 Associated PubMed Articles listed on BioPortfolio]

Controlling Pre-Analytical Process in High-Coverage Quantitative Metabolomics: Spot-Sample Collection for Mouse Urine and Fecal Metabolome Profiling.

Compared to conventional MS and NMR techniques, high-performance chemical isotope labeling (CIL) LC-MS provides accurate relative quantification of many more metabolites in biological samples. However...

Urinary and Plasma Metabolomics Identify the Distinct Metabolic Profile of Disease State in Chronic Mouse Model of Multiple Sclerosis.

Identification of non-invasive biomarkers of disease progression in multiple sclerosis (MS) is critically needed for monitoring the disease progression and for effective therapeutic interventions. Uri...

Untargeted Metabolomics and Inflammatory Markers Profiling in Children With Crohn's Disease and Ulcerative Colitis-A Preliminary Study.

Metabolic profiling might be used to identify disease biomarkers. The aim of our study was to determine the usefulness of untargeted metabolomics analysis to detect differences in serum metabolites be...

Urine and fecal samples targeted metabolomics of carobs treated rats.

Ceratonia siliqua, known as the carob, is considered to be of high nutritional value and of great economic significance due to its unique composition. The beneficial effects of carob against cancer, m...

Metabolomics profiling and pathway analysis of human plasma and urine reveal further insights into the multifactorial nature of Coronary Artery Disease (CAD).

Coronary artery disease (CAD) claims lives yearly. Nuclear magnetic resonance (H NMR) metabolomics analysis is efficient in identifying metabolic biomarkers which lend credence to diagnosis. We identi...

Medical and Biotech [MESH] Definitions

In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.

A study in which observations are made before and after an intervention, both in a group that receives the intervention and in a control group that does not.

An 11-kDa protein associated with the outer membrane of many cells including lymphocytes. It is the small subunit of the MHC class I molecule. Association with beta 2-microglobulin is generally required for the transport of class I heavy chains from the endoplasmic reticulum to the cell surface. Beta 2-microglobulin is present in small amounts in serum, csf, and urine of normal people, and to a much greater degree in the urine and plasma of patients with tubular proteinemia, renal failure, or kidney transplants.

A study that uses observations at multiple time points before and after an intervention (the "interruption"), in an attempt to detect whether the intervention has had an effect significantly greater than any underlying trend over time.

The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.

More From BioPortfolio on "Decipher the Biology of Lethal Prostate Cancer—Using Urine Metabolomics Profiling to Search for Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer Patients"

Quick Search


Relevant Topic

Palliative Care
Palliative care is the active holistic care of patients with advanced progressive illness. Management of pain and other symptoms and provision of psychological, social and spiritual support is paramount. The goal of palliative care is achievement of the ...

Searches Linking to this Trial